Table 3.
Comparison of the nondeath and death groups
| Features | Nondeath (n = 27) | Death (n = 17) | Univariate analysis P-value |
Multivariate analysis OR(95% CI) P-value |
|---|---|---|---|---|
| Sex [Male (%)] | 17 (62.9%) | 11 (64.7%) | 0.91 | |
| Age (years) | 76 (64–82) | 74 (70–80) | 0.84 | |
| Length of stay | 15 (10–26) | 14 (8–32) | 0.98 | |
| TG18 grade | ||||
| II | 12 (44.4%) | 6 (35.3%) | 0.55 | |
| III | 15 (55.6%) | 11 (64.7%) | ||
| aCCI | 4 (3–5) | 7 (5–9) | 0.0010 |
1.53 (1.08–2.17) 0.018 |
| Preoperative body temperature (℃) | 38.0 (36.9–39.0) | 38.3 (37.3–39.3) | 0.41 | |
| Initial laboratory values | ||||
| Platelets (× 109 L) | 172.0 (111.0–290.0) | 249.0 (124.5–374.5) | 0.21 | |
| White blood cells (× 109 L) | 9.32 (6.41–16.04) | 10.66 (7.65–17.08) | 0.56 | |
| Neutrophil granulocyte (%) | 82.4 (74.3–92.6) | 83.4 (81.0–93.0) | 0.32 | |
| ALT (U/L) | 38.0 (23.3–92.0) | 22.0 (13.3–34.0) | 0.014 | |
| STB (μmol/L) | 20.0 (13.4–31.1) | 17.3 (12.1–32.9) | 0.96 | |
| CB (μmol/L) | 1.4 (0–8.0) | 2.9 (0–13.3) | 0.69 | |
| UCB (μmol/L) | 7.8 (3.9–15.5) | 6.3 (2.4–12.5) | 0.56 | |
| Clinical effectiveness | 21 (77.8%) | 11 (64.7%) | 0.55 |
aCCI age-adjusted Charlson comorbidity index; WBC White blood cells; ALT alanine aminotransferase; STB serum total bilirubin; CB conjugated bilirubin; UCB unconjugated bilirubin